{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:03:40Z","timestamp":1792872220833,"version":"4.5.0"},"reference-count":84,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wilhelm Sander-Stiftung","award":["2021.005.1"],"award-info":[{"award-number":["2021.005.1"]}]},{"name":"Wilhelm Sander-Stiftung","award":["2021.005.2"],"award-info":[{"award-number":["2021.005.2"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The impact of the HER4 receptor on the growth and treatment of estrogen receptor-positive breast cancer is widely uncertain. Using CRISPR\/Cas9 technology, we generated stable HER4 knockout variants derived from the HER4-positive MCF-7, T-47D, and ZR-75-1 breast cancer cell lines. We investigated tumor cell proliferation as well as the cellular and molecular mechanisms of tamoxifen, abemaciclib, AMG232, and NRG1 treatments as a function of HER4 in vitro. HER4 differentially affects the cellular response to tamoxifen and abemaciclib treatment. Most conspicuous is the increased sensitivity of MCF-7 in vitro upon HER4 knockout and the inhibition of cell proliferation by NRG1. Additionally, we assessed tumor growth and immunological effects as responses to tamoxifen and abemaciclib therapy in humanized tumor mice (HTM) based on MCF-7 HER4-wildtype and the corresponding HER4-knockout cells. Without any treatment, the enhanced MCF-7 tumor growth in HTM upon HER4 knockout suggests a tumor-suppressive effect of HER4 under preclinical but human-like conditions. This phenomenon is associated with an increased HER2 expression in MCF-7 in vivo. Independent of HER4, abemaciclib and tamoxifen treatment considerably inhibited tumor growth in these mice. However, abemaciclib-treated hormone receptor-positive breast cancer patients with tumor-associated mdm2 gene copy gains or pronounced HER4 expression showed a reduced event-free survival. Evidently, the presence of HER4 affects the efficacy of tamoxifen and abemaciclib treatment in different estrogen receptor-positive breast cancer cells, even to different extents, and is associated with unfavorable outcomes in abemaciclib-treated patients.<\/jats:p>","DOI":"10.3390\/ijms25137475","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T12:21:03Z","timestamp":1720441263000},"page":"7475","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice"],"prefix":"10.3390","volume":"25","author":[{"given":"Veruschka","family":"Albert","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Medical Center Regensburg, 93935 Regensburg, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bruss","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Medical Center Regensburg, 93935 Regensburg, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"T\u00fcmen","sequence":"additional","affiliation":[{"name":"Bavarian Cancer Research Center (BZKF), 93053 Regensburg, Germany"},{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Piendl","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Medical Center Regensburg, 93935 Regensburg, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-8828","authenticated-orcid":false,"given":"Florian","family":"Weber","sequence":"additional","affiliation":[{"name":"Bavarian Cancer Research Center (BZKF), 93053 Regensburg, Germany"},{"name":"Institute of Pathology, University of Regensburg, 93093 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8439-7994","authenticated-orcid":false,"given":"Edgar","family":"Dahl","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Seitz","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Medical Center Regensburg, 93935 Regensburg, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Ortmann","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Medical Center Regensburg, 93935 Regensburg, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8838-0532","authenticated-orcid":false,"given":"Anja K.","family":"Wege","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Medical Center Regensburg, 93935 Regensburg, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8398-8349","authenticated-orcid":false,"given":"Gero","family":"Brockhoff","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Medical Center Regensburg, 93935 Regensburg, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"110401","DOI":"10.1016\/j.cellsig.2022.110401","article-title":"\u201cShedding\u201d light on HER4 signaling in normal and malignant breast tissues","volume":"97","author":"Brockhoff","year":"2022","journal-title":"Cell. Signal."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1158\/0008-5472.CAN-04-3150","article-title":"Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells","volume":"65","author":"Junttila","year":"2005","journal-title":"Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1091\/mbc.e05-05-0402","article-title":"Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth","volume":"17","author":"Sundvall","year":"2006","journal-title":"Mol. Biol. Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/jcb.20815","article-title":"Ligand-independent regulation of ErbB4 receptor phosphorylation by activated Ras","volume":"98","author":"Erlich","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41388-018-0465-z","article-title":"Gamma-secretase-dependent signaling of receptor tyrosine kinases","volume":"38","author":"Merilahti","year":"2019","journal-title":"Oncogene"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hollm\u00e9n, M., Liu, P., Kurppa, K., Wildiers, H., Reinvall, I., Vandorpe, T., Smeets, A., Deraedt, K., Vahlberg, T., and Joensuu, H. (2012). Proteolytic processing of ErbB4 in breast cancer. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039413"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1050-1738(01)00065-2","article-title":"Erbb4 and its isoforms: Selective regulation of growth factor responses by naturally occurring receptor variants","volume":"10","author":"Junttila","year":"2000","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1158\/0008-5472.CAN-05-2368","article-title":"The ERBB4\/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells","volume":"66","author":"Naresh","year":"2006","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1158\/0008-5472.CAN-08-0538","article-title":"The HER4\/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis","volume":"68","author":"Naresh","year":"2008","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1476-4598-9-150","article-title":"The ER\u03b1 coactivator, HER4\/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium","volume":"9","author":"Rokicki","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_11","first-page":"323","article-title":"Direct coupling of the HER4 intracellular domain (4ICD) and STAT5A signaling is required to induce mammary epithelial cell differentiation","volume":"7","author":"Han","year":"2016","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1128\/MCB.21.13.4265-4275.2001","article-title":"Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells","volume":"21","author":"Sartor","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.18632\/oncotarget.26867","article-title":"Target HER four in breast cancer?","volume":"10","author":"Brockhoff","year":"2019","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1158\/0008-5472.CAN-05-4397","article-title":"Coregulation of estrogen receptor by ERBB4\/HER4 establishes a growth-promoting autocrine signal in breast tumor cells","volume":"66","author":"Zhu","year":"2006","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10911-008-9079-3","article-title":"Role of ErbB4 in breast cancer","volume":"13","author":"Sundvall","year":"2008","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"ref_16","first-page":"10","article-title":"Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant","volume":"1","author":"Gallo","year":"2013","journal-title":"J. Cancer Res. Ther. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/jcp.56.4.300","article-title":"Type 1 growth factor receptor expression in node positive breast cancer: Adverse prognostic significance of c-erbB-4","volume":"56","author":"Lodge","year":"2003","journal-title":"J. Clin. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13058-018-1072-1","article-title":"HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women","volume":"20","author":"Wege","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.18632\/oncotarget.1232","article-title":"HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma","volume":"4","author":"Portier","year":"2013","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/bcr2339","article-title":"Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer","volume":"11","author":"Sassen","year":"2009","journal-title":"Breast Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40259-019-00337-6","article-title":"CDK4\/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib","volume":"33","author":"Eggersmann","year":"2019","journal-title":"BioDrugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"George, M.A., Qureshi, S., Omene, C., Toppmeyer, D.L., and Ganesan, S. (2021). Clinical and Pharmacologic Differences of CDK4\/6 Inhibitors in Breast Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.693104"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Papadimitriou, M.C., Pazaiti, A., Iliakopoulos, K., Markouli, M., Michalaki, V., and Papadimitriou, C.A. (2022). Resistance to CDK4\/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer. Biochim. Biophys. Acta Mol. Cell Res., 1869.","DOI":"10.1016\/j.bbamcr.2022.119346"},{"key":"ref_25","first-page":"63","article-title":"HDM2 and HDMX Proteins in Human Cancer","volume":"31","year":"2018","journal-title":"Klin. Onkol."},{"key":"ref_26","first-page":"1001","article-title":"The MDM2-p53 interaction","volume":"1","author":"Moll","year":"2003","journal-title":"Mol. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/387299a0","article-title":"Regulation of p53 stability by Mdm2","volume":"387","author":"Kubbutat","year":"1997","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"a026336","DOI":"10.1101\/cshperspect.a026336","article-title":"The Role of MDM2 Amplification and Overexpression in Tumorigenesis","volume":"6","author":"Oliner","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.biocel.2007.03.022","article-title":"MDM2 and MDM4: P53 regulators as targets in anticancer therapy","volume":"39","author":"Toledo","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-12-0053","article-title":"Molecular pathways: Targeting Mdm2 and Mdm4 in cancer therapy","volume":"19","author":"Li","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/bjc.1995.189","article-title":"Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status","volume":"71","author":"McCann","year":"1995","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/(SICI)1097-0215(19971021)74:5<529::AID-IJC9>3.0.CO;2-5","article-title":"p21\/waf1\/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis","volume":"74","author":"Jiang","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_33","first-page":"71","article-title":"Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells","volume":"1","author":"Gudas","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ijc.33911","article-title":"mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease","volume":"150","author":"Wege","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: An important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"25937","DOI":"10.1074\/jbc.M116.752303","article-title":"Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex: IMPLICATION OF A NOVEL MDMX SER-314 PHOSPHOSITE","volume":"291","author":"Gerarduzzi","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"30783","DOI":"10.1074\/jbc.M506057200","article-title":"Secretase-dependent tyrosine phosphorylation of Mdm2 by the ErbB-4 intracellular domain fragment","volume":"280","author":"Arasada","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","article-title":"A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes","volume":"10","author":"Neve","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Jiang, G., Zhang, S., Yazdanparast, A., Li, M., Pawar, A.V., Liu, Y., Inavolu, S.M., and Cheng, L. (2016). Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genom., 17.","DOI":"10.1186\/s12864-016-2911-z"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/ijc.26159","article-title":"Humanized tumor mice\u2014A new model to study and manipulate the immune response in advanced cancer therapy","volume":"129","author":"Wege","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Pandey, K., Katuwal, N.B., Park, N., Hur, J., Cho, Y.B., Kim, S.K., Lee, S.A., Kim, I., Lee, S.-R., and Moon, Y.W. (2022). Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2\/M Cell Cycle Phase. Cancers, 14.","DOI":"10.3390\/cancers14010210"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early Adaptation and Acquired Resistance to CDK4\/6 Inhibition in Estrogen Receptor-Positive Breast Cancer","volume":"76","author":"Palafox","year":"2016","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Portman, N., Chen, J., and Lim, E. (2021). MDM2 as a Rational Target for Intervention in CDK4\/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.777867"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13058-020-01318-2","article-title":"MDM2 inhibition in combination with endocrine therapy and CDK4\/6 inhibition for the treatment of ER-positive breast cancer","volume":"22","author":"Portman","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8442","DOI":"10.1038\/sj.onc.1205960","article-title":"Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation","volume":"21","author":"Hobbs","year":"2002","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"89284","DOI":"10.18632\/oncotarget.18467","article-title":"A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer","volume":"8","author":"Mota","year":"2017","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","article-title":"ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling","volume":"16","author":"Beerli","year":"1997","journal-title":"EMBO J."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Saeki, Y., Endo, T., Ide, K., Nagashima, T., Yumoto, N., Toyoda, T., Suzuki, H., Hayashizaki, Y., Sakaki, Y., and Okada-Hatakeyama, M. (2009). Ligand-specific sequential regulation of transcription factors for differentiation of MCF-7 cells. BMC Genom., 10.","DOI":"10.1186\/1471-2164-10-545"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ijc.22360","article-title":"Expression and differential signaling of heregulins in pancreatic cancer cells","volume":"120","author":"Kolb","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1023\/A:1020682807922","article-title":"Heregulin-induced apoptosis","volume":"7","author":"Le","year":"2002","journal-title":"Apoptosis"},{"key":"ref_51","first-page":"883","article-title":"Constitutive expression of Heregulin induces apoptosis in an erbB-2 overexpressing breast cancer cell line SKBr-3","volume":"15","author":"Scott","year":"1999","journal-title":"Int. J. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1111\/cas.14458","article-title":"Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody-dependent HER4 intracellular domain trafficking","volume":"111","author":"Lanotte","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00292-022-01096-y","article-title":"Pr\u00e4diktive molekulare Diagnostik beim Mammakarzinom: Welche Anforderungen stellen sich heute und in Zukunft f\u00fcr die Pathologie?","volume":"43","author":"Wild","year":"2022","journal-title":"Pathologie"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/138920206779315737","article-title":"Estrogen signaling multiple pathways to impact gene transcription","volume":"7","author":"Marino","year":"2006","journal-title":"Curr. Genom."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.bbrc.2013.11.111","article-title":"HER4 selectively coregulates estrogen stimulated genes associated with breast tumor cell proliferation","volume":"443","author":"Han","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"69493","DOI":"10.18632\/oncotarget.17778","article-title":"Preclinical characterization of abemaciclib in hormone receptor positive breast cancer","volume":"8","author":"Calsina","year":"2017","journal-title":"Oncotarget"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/path.1370","article-title":"Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer","volume":"200","author":"Witton","year":"2003","journal-title":"J. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"R246","DOI":"10.1186\/bcr783","article-title":"Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling","volume":"6","author":"Tovey","year":"2004","journal-title":"Breast Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/bcr1843","article-title":"Cytogenetic analysis of HER1\/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients","volume":"10","author":"Sassen","year":"2008","journal-title":"Breast Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Machleidt, A., Buchholz, S., Diermeier-Daucher, S., Zeman, F., Ortmann, O., and Brockhoff, G. (2013). The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-437"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.2353\/ajpath.2009.090204","article-title":"Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients","volume":"175","author":"Thor","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.18632\/oncotarget.2002","article-title":"The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer","volume":"5","author":"Fujiwara","year":"2014","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s11845-022-02926-x","article-title":"Breast cancer recurrence: Factors impacting occurrence and survival","volume":"191","author":"Courtney","year":"2022","journal-title":"Ir. J. Med. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4174\/astr.2023.104.1.1","article-title":"Prognosis according to the timing of recurrence in breast cancer","volume":"104","author":"Lee","year":"2023","journal-title":"Ann. Surg. Treat. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","article-title":"The CDK4\/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade","volume":"22","author":"Schaer","year":"2018","journal-title":"Cell Rep."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Dhatchinamoorthy, K., Colbert, J.D., and Rock, K.L. (2021). Cancer Immune Evasion through Loss of MHC Class I Antigen Presentation. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.636568"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"108944","DOI":"10.1016\/j.celrep.2021.108944","article-title":"Metabolic modulation by CDK4\/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors","volume":"35","author":"Uzhachenko","year":"2021","journal-title":"Cell Rep."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wang, X., Zhao, S., Xin, Q., Zhang, Y., Wang, K., and Li, M. (2024). Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer. Cancer Gene Ther.","DOI":"10.1038\/s41417-024-00747-x"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"eaav7171","DOI":"10.1126\/scitranslmed.aav7171","article-title":"MDM2 antagonists overcome intrinsic resistance to CDK4\/6 inhibition by inducing p21","volume":"11","author":"Vilgelm","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"8534","DOI":"10.1158\/0008-5472.CAN-04-1945","article-title":"Prognostic relevance of gene amplifications and coamplifications in breast cancer","volume":"64","author":"Schraml","year":"2004","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jmcb\/mjx007","article-title":"The role of MDM2 and MDM4 in breast cancer development and prevention","volume":"9","author":"Haupt","year":"2017","journal-title":"J. Mol. Cell Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.18632\/oncotarget.3364","article-title":"MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition","volume":"6","author":"Kovatcheva","year":"2015","journal-title":"Oncotarget"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/s41388-020-1354-9","article-title":"Senescence as a therapeutically relevant response to CDK4\/6 inhibitors","volume":"39","author":"Wagner","year":"2020","journal-title":"Oncogene"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Miserocchi, G., Bocchini, M., Cortesi, M., Arienti, C., de Vita, A., Liverani, C., Mercatali, L., Bravaccini, S., Ulivi, P., and Zanoni, M. (2023). Combining preclinical tools and models to unravel tumor complexity: Jump into the next dimension. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1171141"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2184.2007.00449.x","article-title":"Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation","volume":"40","author":"Brockhoff","year":"2007","journal-title":"Cell Prolif."},{"key":"ref_79","first-page":"684","article-title":"Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors","volume":"79","author":"Breindl","year":"2011","journal-title":"Cytom. A"},{"key":"ref_80","first-page":"8.6.1","article-title":"Dynamic proliferation assessment in flow cytometry","volume":"48","author":"Brockhoff","year":"2010","journal-title":"Curr. Protoc. Cell Biol."},{"key":"ref_81","first-page":"535","article-title":"Cell type specific applicability of 5-ethynyl-2\u2032-deoxyuridine (EdU) for dynamic proliferation assessment in flow cytometry","volume":"75","author":"Clarke","year":"2009","journal-title":"Cytom. A"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.18632\/oncotarget.13159","article-title":"IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM)","volume":"8","author":"Wege","year":"2017","journal-title":"Oncotarget"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12967-020-02484-9","article-title":"A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)","volume":"18","author":"Wege","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/his.13253","article-title":"HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes\u2014Reclassifying cases in the equivocal category","volume":"71","author":"Holzschuh","year":"2017","journal-title":"Histopathology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/7475\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:11:32Z","timestamp":1760109092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/7475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":84,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ijms25137475"],"URL":"https:\/\/doi.org\/10.3390\/ijms25137475","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]}}}